Target intelligence / Profile preview

Intestinal fungus (null)

Target
null
Molecular classification
Other
01

Overview

"Intestinal fungi" refers to the diverse community of fungal organisms—collectively termed the gut mycobiome—inhabiting the human gastrointestinal tract. These fungi form a minor but important component of the overall gut microbiota, which also includes bacteria, viruses, and archaea. The predominant fungal phyla found in the gut include Ascomycota, Basidiomycota, and Zygomycota, with common genera such as *Candida*, *Saccharomyces*, and *Penicillium*[6][5]. Fungi generally constitute less than 1% of the gut microbial population by cell number, but their larger cell size makes them a significant contributor to gut biomass[5]. Intestinal fungi interact dynamically with bacterial microbiota and the host, influencing immune system development, metabolic processes, and potentially the pathogenesis of various diseases—particularly when the normal balance is disrupted[2][4][6]. However, "intestinal fungi" is not a single molecular target or receptor and should not be classified as such for drug targeting or molecular annotation purposes[6].

Other names
Gut mycobiomeFungal component of gut microbiotaGut fungiIntestinal mycobiota
02

Mechanism of action

- Inhibition of fungal growth (antifungals target ergosterol synthesis, membrane function, etc.) - Competition/interference with bacterial populations (probiotics/antibiotics)

03

Biological functions

Immune response modulationInfluence on metabolic processesInteractions with bacteria and gut ecologyContribution to intestinal and systemic inflammation
04

Disease associations

Infection (opportunistic pathogenicity of species like *Candida albicans*)Inflammation (may influence colitis and other inflammatory diseases)Other (potential effects on allergy, metabolic disease, and overall gut health)
05

Safety considerations

Overgrowth of pathogenic fungi under immunosuppression or antibiotic use (especially *Candida*, leading to invasive candidiasis or dysbiosis)Challenges in maintaining mycobiome balance; antifungal resistance
06

Interacting drugs

Antifungals (e.g., fluconazole, amphotericin B; act broadly against gut fungi)

1 more in the full profile.

07

Biomarkers

Detection of fungal DNA/sequences in stool (e.g., via next-generation sequencing of ITS regions for fungi)Abundance or diversity of specific fungal taxa as potential disease markers

Beyond the preview

Go deeper on Intestinal fungus (null).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Intestinal fungus (null).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call